• No results found

DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service

N/A
N/A
Protected

Academic year: 2021

Share "DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service"

Copied!
5
0
0

Loading.... (view fulltext now)

Full text

(1)

DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration

5100 Paint Branch Parkway College Park, Maryland 20740

Mr. Robert DeWitty, Esq.

Outsource Product Manufacture LLC 111 S. Calvert Street, Suite 2700 Baltimore, Maryland 2 1202

Dear Mr. DeWitty:

This is to inform you that the notification dated, December 15,2003, that you submitted pursuant to 21 U.S.C. 350b(a)(2) (section 413(a)(2) of the Federal Food, Drug, and Cosmetic Act (the Act)) was filed by the Food and Drug Administration (FDA) on January 7,2004. Your notification concerns the substance called “VI-28” which consists of Panax ginseng, Cornu cervipantotrichum, Cuscuta chinesis, Cnidium monnieri, and Kaempferia galanga that you intend to market as a new dietary ingredient.

According to the notification, you intend to sell 300 milligram (mg) capsules containing 75 mg of Panax ginseng, 75 mg Cornu cervipantotrichum, 60 mg Cnidium monnieri, 60 mg Cuscuta chinesis, and 30 mg of Kaempferia galanga. Under the conditions of use stated in the labeling of your

product, the manufacturer recommends that the dietary supplement “VI-28” be used in the following manner: 2 capsules daily for the first month, 2 capsules every two days for the second and third months, and 2 capsules twice a week for the fourth and following months.

Under 21 U.S.C. 350b(a), the manufacturer or distributor of a dietary supplement containing a new dietary ingredient that has not been present in the food supply as an article used for food in a form in which the food has not been chemically altered must submit to FDA, at least 75 days before the dietary ingredient is introduced or delivered for introduction into interstate commerce, information that is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing such new dietary ingredient will reasonably be expected to be safe. FDA reviews this information to determine whether it provides an adequate basis for such a conclusion. Under section 350b(a)(2), there must be a history of use or other evidence of safety establishing that the new dietary ingredient, when used under the conditions recommended or suggested in the labeling of the dietary supplement, will reasonably be expected to be safe. If this requirement is not met, the dietary

supplement is considered to be adulterated under 2 1 U.S.C. 342(f)(l)(B) because there is inadequate information to provide reasonable assurance that the new dietary ingredient does not present a significant or unreasonable risk of illness or injury.

(2)

.

Page 2- Mr. Robert DeWitty

FDA has carefully considered the information in your submission, and the agency has concerns about the evidence on which you rely to support your conclusion that a dietary supplement containing “VI- 28” will reasonably be expected to be safe.

Your notification fails to identify the Latin binomial including the author of the new dietary

ingredients in “VI-28” as required for any herb or other botanical by Federal regulations found in 2 1 CFR 190.6(b)(2). S ince the notification did not include the Latin binomial and author for Panax ginseng, Cnidium monnieri, and Kaempferia galanga, it is impossible for FDA to identify which varieties of botanicals were used in the “VI-28” capsules which you intend to market.

Your notification does not fully describe the chemical composition of the components in “VI-28”, including a description of the method of preparation. A description of the method of manufacturing may have helped FDA identify your product. There were also discrepancies with the description of the test articles used in studies cited in your notification. For example, one study reported that it was conducted with “VI-28”. Other studies cited were conducted with test substances that may be similar to “VI-28”, however, the relationship of these test materials to the botanical preparations that are the subject of the notification was not stated. Therefore, it is unclear how the information submitted relates qualitatively and quantitatively to the proposed new dietary ingredient called “VI-28”. For the reasons discussed above, the information in your submission does not provide an adequate basis to conclude that your product containing “VI-28,” when used under the conditions

recommended or suggested in the labeling of your product, will reasonably be expected to be safe. Therefore, your product may be adulterated under 21 U.S.C. 342(f)(l)(B) as a dietary supplement that contains a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. Introduction of such a product into interstate commerce is prohibited under 21 U.S.C. 33 1 (a) and (v). Your notification will be kept confidential for 90 days after the filing date of January 7,2004. After the go-day date, the notification will be placed on public display at FDA’s Docket Management Branch in docket number 95S-03 16. Prior to that date, you may wish to identify in writing

specifically what information you believe is proprietary, trade secret or otherwise confidential for FDA’s consideration.

(3)

.

Pa’ge 3- Mr. Robert DeWitty

If you have any questions concerning this matter, please contact Victoria Lutwak at (301) 436-2375.

Sincerely yours,

Susan J. Walker, M.D. Director

Division of Dietary Supplement Programs Office of Nutritional Products, Labeling

and Dietary Supplements Center for Food Safety

(4)

,’ l *

O u tso u r c e P r o d u c t M a n u fa c tu r e L L C

t

v intellectual P r o p e i i y - P r o d u c t D e v e l o p m e n t - R e g u l a t o r y C o m p l i a n c e C o n c e r n s % P a R B ! & & E J R o b e r t M. DeWittY, E s q . f - S r i % - S F s p A i l m m W e n d e l J. A s k e w , Esq.* *licensed in Connecticut.

1 1 1 S . Calvert S treet, S u i t e 2 7 0 0 8 1 7 Silver S p r i n g A v e n u e , S u i t e 2 0 2 B A L T I M O R E , M a r y l a n d 2 1 2 0 2 S I L V E R S P R I N G , M a r y l a n d 2 0 9 lo T E L E : 4 1 O - 5 3 9 - 6 9 6 9 / 3 0 1 - 6 5 0 - 5 9 0 0 / 8 8 8 - 7 9 5 - 6 8 6 3 H o n a K o n a O ffice F A X : 4 1 0 - 5 1 0 - 1 9 7 3 S u i t e 1 8 0 5 2 1 J a n u a r y 2 0 0 4 2 0 P e c i d e r S treet W h e e k x k H o u s e C e n t r a l S u s a n W a lker, M .D. H O N G K O N G Division Director 1 Division o f Dietary S u p p l e m e n t

O ffice o f N u tritional P roducts, L a b e l i n g , a n d Dietary S u p p l e m e n ts C e n te r fo r F o o d S a fe ty a n d N u trition F o o d a n d D r u g A d m inistration 5 1 0 0 P a i n t B r a n c h P a r k w a y C o l l e g e Park, M a r y l a n d 2 0 7 4 0 - 3 8 3 5 V IA F A C S IM IL E C o u fie s y c o p y to F o l l o w R e : N e w Dietary S u p p l e m e n t V I-28 P re-market N o tification O u r R e f: V i a c o n i c = l

A T T N Dr. W a lker:

This letter is written to clarify th e intentions o f th e P re-market N o tification d a te d 1 5 D e c e m b e r 2 0 0 3 (filing d a te 7 J a n u a r y 2 0 0 4 ) .

O u r intention o f th e P re-market N o tification w a s to o b ta i n a p p r o v a l to m a r k e t o n e (1) dietary i n g r e d i e n t c a l l e d V I-28 w h i c h consists o f R A D IX G I N S E N G , C O R N U C E R V I P A N T O T R I C H U M , F R U C T U S C N IDII, S E M E N C U S C U T A E , a n d R H IZO M A K A E M P F E R IA E .

lf y o u h a v e a n y q u e s tio n s o r c o n c e r n s , fe e l free to c o n tact o u r o ffices via fa x o r p h o n e .

(5)

Outsource

Product Manufacture

LLC

lnte/lectual Property- Product Development - Regulatory Compliance Concerns

3% P% RB! iwzl

Robert M. DeWitty, Esq. -ii&%- xl%.f t&m

Wendel J. Askew, Esq.*

*Licensed In Connecticut

G&3aILVER SPRING, Maryland 20910

1 1 1 S. Culvert Street Suite 2700 817 Silver Spring Avenue, Suite 202

TELE: 4 1 O-539-6969 / 30 l-650-5900 / 888-795-6863 Hona Kona Office

FAX: 41 O-51 O-l 973

Suite 1805 Wheelock House 20 Pedder Street Central HONG KONG 15 December 2003 Division of Standards and Labeling Requirements

Office of Nutritional Products, Labeling, and Dietary Supplements Center for Food Safety and Nutrition

Food and Drug Administration 5100 Paint Branch Parkway

College Park, Maryland 20740-3835

Re: 75-day Pre-market Notification for New Dietary Ingredients: Radix ginseng, Cornu Cervi Pantotrichum, Fructus Cnidii, Semen Cuscutae, Rhizoma Kaempferiae

Dear Sir or Madam:

Pursuant to 413 of the Federal Food, Drug and Cosmetic Act, and 21 C.F.R. section 190.6, please find attached pre-market notifications for the Ingredients Radix ginseng, Cornu Cervi Pantotrichum, Fructus Cnidii, Semen Cuscutae, and Rhizoma Kaempferiae to be used in the dietary supplement VI- 28, which Outsource Product Manufacture LLC is forwarding as counsel to the submitter, Vigconic (International) Ltd. of Hong Kong, SARHK.

We have enclosed discussions of the scientific data and literature showing the Ingredients, when used under the conditions suggested in the labeling of VI-28, will reasonably be expected to be safe.

An original and two copies of the pre-market notifications have been enclosed. If you have any questions or concerns, feel free to contact our offices via fax, phone, or email.

Robert DeWitty, Esq. ‘, Enclosures.

References

Related documents

• Develop and agree an integrated (Project & O&M) IM strategy • Engage stakeholders early and establish understanding of IM role • Establish standards & procedures early

At present, every third Internet user visits the websites of fashion brands and as far as the market of social media is concerned, the leading position is occupied by the brands

This test can distinguish between the aforementioned model, which inflation—output link is spurious from the competing hypothesis that there are numerous structural institutional

The Permanent interuniversity Seminar in Bioethics is performed by a combined face‐to‐face meetings and online exchanges that allow the generation of knowledge in

The Black community is internally diverse, and Black students are navigating multiple intersecting identities, including [dis]abilities (Steward, 2008, 2009). The reality is that

B ob’s experience provides just one example of the importance of consulting with a Certified Elder Law Attorney who is accredited by the Department of Veterans Affairs to

Methods: In the SWiss Venous ThromboEmbolism Registry, 257 cancer patients (61 6 15 years) with acute VTE and prior hospitalization for acute medical illness or surgery within 30

These were always your cheekbones, taut as a Least Tern’s that look off, landlocked, toward the gulf and the home you grew up in washed away along with half of the